Structure Therapeutics (NASDAQ:GPCR) Earns “Overweight” Rating from Cantor Fitzgerald

Structure Therapeutics (NASDAQ:GPCR)‘s stock had its “overweight” rating reissued by Cantor Fitzgerald in a research report issued to clients and investors on Monday, Benzinga reports. They presently have a $65.00 price objective on the stock. Cantor Fitzgerald’s target price indicates a potential upside of 69.09% from the stock’s current price.

A number of other research analysts also recently weighed in on GPCR. BMO Capital Markets raised their target price on shares of Structure Therapeutics from $83.00 to $100.00 and gave the company an “outperform” rating in a research report on Friday, June 7th. JPMorgan Chase & Co. assumed coverage on Structure Therapeutics in a report on Tuesday, May 21st. They issued an “overweight” rating and a $65.00 price objective for the company. Finally, JMP Securities dropped their target price on Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating on the stock in a report on Friday, August 9th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Structure Therapeutics currently has an average rating of “Buy” and an average target price of $84.63.

Structure Therapeutics Price Performance

GPCR opened at $38.44 on Monday. The company has a market capitalization of $1.79 billion, a price-to-earnings ratio of -49.92 and a beta of -3.52. The business’s 50-day moving average price is $38.16 and its two-hundred day moving average price is $39.65. Structure Therapeutics has a 1 year low of $26.61 and a 1 year high of $75.02.

Structure Therapeutics (NASDAQ:GPCR) last announced its earnings results on Thursday, August 8th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.05. Sell-side analysts anticipate that Structure Therapeutics will post -0.86 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Structure Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of GPCR. Sandia Investment Management LP bought a new position in Structure Therapeutics during the second quarter worth about $39,000. Quarry LP bought a new position in shares of Structure Therapeutics during the 2nd quarter worth approximately $79,000. Sectoral Asset Management Inc. acquired a new position in shares of Structure Therapeutics during the 4th quarter worth approximately $139,000. ADAR1 Capital Management LLC acquired a new position in shares of Structure Therapeutics during the 4th quarter worth approximately $163,000. Finally, Sei Investments Co. bought a new stake in Structure Therapeutics in the 2nd quarter valued at $212,000. 91.78% of the stock is owned by institutional investors.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.